The highlights of ERS 2019 by Jan De Backer, CEO of Fluidda
At ERS 2019, Jan de Backer, CEO of Fluidda, explains why during the past years, the treatment of lung diseases is shifting from using more common bronchodilatators to more personalized medicine with biologicals and new devices.
This shift calls for new diagnostic tools to match the heterogeneity of the patients with the heterogeneity of treatments to optimize the treatment of every individual patient.
Be sure to follow us on on LinkedIn to make sure you don’t miss out on any FRI-related research!
Categorised in: Conferences / October 24, 2019 4:21 pm /Tags: bronchodilators, ERS